Message #6 From:
NewsBot Date: December 1, 2006 09:00:00 AM
AMAR News Dutton Associates Announces Investment Opinion: Amarillo Biosciences Speculative Buy Rating Reiterated in Update Report by Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates updates its coverage of Amarillo Biosciences, Inc.
(OTCBB:AMAR), maintaining its Speculative Buy rating and a 15- to
18-month price target of $1.90. The 12-page report by Dutton Associates
senior analyst Wayne M. Lottenville, CFA is available at www.jmdutton.com
as well as from First Call, Bloomberg, Zacks, Reuters, and Knobias and
other leading financial portals. Amarillo Biosciences is a
biopharmaceutical company developing low-dose oral natural human
interferon-alpha as a safe, cost-effective therapy for several diseases
or their symptoms, including influenza and HIV-related oral warts. The
Company has a Phase 2 clinical investigation using oral low-dose
interferon-alpha for Behcet's disease now underway and plans to begin
enrollment in a Phase 2 clinical trial in December to treat oral warts
in HIV-positive patients. Influenza and chronic cough trials may begin
in 2007.
About Dutton Associates
Dutton Associates is one of the largest independent investment research
firms in the U.S. Its 28 senior analysts are primarily CFAs, and have
expertise in many industries. Dutton Associates provides continuing
analyst coverage of 140 enrolled companies, and its research, estimates,
and ratings are carried in all the major databases serving institutions
and online investors.
The current cost of enrollment in our one-year continuing research
program is US $39,500 prepaid for 4 Research Reports, typically
published quarterly, and requisite Research Notes. Dutton Associates
received $35,000 from the Company for 4 Research Reports with coverage
commencing on 9/18/06. The Firm does not accept any equity compensation.
Our principals and analysts are prohibited from owning or trading in
securities of covered companies. The views expressed in this research
report accurately reflect the analyst's personal views about the subject
securities or issuer. Neither the analyst's compensation nor the
compensation received by us is in any way related to the specific
ratings or views contained in this research report or note. Please read
full disclosures and analyst background at www.jmdutton.com
before investing.
